Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from <scp>HIV</scp> viral suppression in children and adolescents who transitioned from ritonavir‐boosted lopinavir‐ to dolutegravir‐based antiretroviral therapy in <scp>Lesotho</scp>. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
2022 · External reference
Unresolved reference
2016 · External reference
Dolutegravir as first‐ or second‐line treatment for HIV‐1 infection in children
10.1056/nejmoa2108793 · 2021 · External reference
Second‐line antiretroviral therapy for children living with HIV in Africa
10.1056/nejmoa2404597 · 2025 · External reference
HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study
10.1097/qad.0000000000003835 · 2024 · External reference
Cohort profile: the viral load cohort north‐East Lesotho (VICONEL) from 2016 to 2023 ‐ cohort description, test volumes, predictors of viraemia and the road ahead
10.1136/bmjopen-2024-085404 · 2025 · External reference
Unresolved reference
2019 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2020 · External reference
Second‐line switch to dolutegravir for treatment of HIV infection
10.1056/nejmoa2210005 · 2023 · External reference
Dolutegravir versus ritonavir‐boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV‐1 infection in whom first‐line therapy has failed (DAWNING): an open‐label, non‐inferiority, phase 3b trial
10.1016/s1473-3099(19)30036-2 · 2019 · External reference
Two‐year outcomes of treatment‐experienced adults after programmatic transitioning to dolutegravir: longitudinal data from the VICONEL human immunodeficiency virus cohort in Lesotho
10.1093/cid/ciad390 · 2023 · External reference
Virological and drug‐resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR‐supported countries: a prospective cohort study
10.1016/s2352-3018(25)00162-6 · 2025 · External reference
Realizing the promise of dolutegravir in effectively treating children and adolescents living with HIV in real‐world settings in 6 countries in eastern and southern Africa
10.1097/inf.0000000000003878 · 2023 · External reference
Emergence of acquired dolutegravir resistance in treatment‐experienced people with HIV in Lesotho
10.1093/cid/ciae185 · 2024 · External reference
Predicted dolutegravir resistance in people living with HIV in South Africa during 2020–35: a modelling study
10.1016/s2214-109x(24)00553-9 · 2025 · External reference
